Skip to content
ChickenStockChickenStock
ResearchRLAY
Relay Therapeutics logo

Relay Therapeutics (RLAY) stock

NASDAQ

$18.10+0.11%(+0.02)

As of the Nov 13, 2026 close (U.S. Eastern)

Events and reference metrics · 1

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

-13.61x

Net loss — not comparable

P/B

4.88x

P/S

400.00x

Latest earnings

SEC filings

Jul–Sep 2026(FY2026 Q3)

Operating income decreased from the same period a year earlier.

Key reported figures come first. Select one to see the same quarter across three years.

See the same quarter across three years →

Filed Nov 4, 2026 · 10-Q · SEC EDGAR

Reported results are from SEC EDGAR filings. Reference information only, not investment advice.

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

16 SEC filings
  • Bergstrom Donald APresident, R&D · Oct 28, 2026Open-market sale2,252 shares · $42K
    Avg. price $18.62396,878 shares held after
  • Catinazzo ThomasChief Financial Officer · Oct 28, 2026Open-market sale1,469 shares · $27K
    Avg. price $18.62103,665 shares held after
  • Rahmer PeterSee remarks · Oct 28, 2026Open-market sale753 shares · $14K
    Avg. price $18.62222,904 shares held after
  • Patel SanjivPresident and CEO · Oct 7, 2026Open-market sale48,199 shares · $872K
    Avg. price $18.1471,301 shares held after
  • Catinazzo ThomasChief Financial Officer · Oct 6, 2026Open-market sale17,717 shares · $329K
    Avg. price $18.5879
    Show 2 price lots
    • 17,511 shares × $18.58$325K
    • 206 shares × $19.26$4K
  • Patel SanjivPresident and CEO · Sep 8, 2026Open-market sale48,199 shares · $913K
    Avg. price $18.94519,500 shares held after
  • Catinazzo ThomasChief Financial Officer · Sep 8, 2026Open-market sale17,717 shares · $336K
    Avg. price $18.94122,851 shares held after
  • Bergstrom Donald APresident, R&D · Sep 8, 2026Open-market sale8,530 shares · $162K
    Avg. price $18.97399,130 shares held after
  • Rahmer PeterSee remarks · Aug 26, 2026Open-market sale4,508 shares · $90K
    Avg. price $20.03223,657 shares held after
  • SVF Pauling (Cayman) Ltd10% owner · Aug 25, 2026Open-market sale6,000,000 shares · $116.4M
    Avg. price $19.421,904,963 shares held after
  • Patel SanjivPresident and CEO · Aug 17, 2026Open-market sale48,199 shares · $980K
    Avg. price $20.33567,699 shares held after
  • Catinazzo ThomasChief Financial Officer · Aug 14, 2026Open-market sale17,717 shares · $350K
    Avg. price $19.74140,568 shares held after
  • Bergstrom Donald APresident, R&D · Jul 28, 2026Open-market sale2,237 shares · $42K
    Avg. price $18.61407,660 shares held after
  • Catinazzo ThomasChief Financial Officer · Jul 28, 2026Open-market sale1,459 shares · $27K
    Avg. price $18.61158,285 shares held after
  • Rahmer PeterSee remarks · Jul 28, 2026Open-market sale748 shares · $14K
    Avg. price $18.61228,165 shares held after

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Relay Therapeutics (RLAY) stock information

NASDAQ

Relay Therapeutics (RLAY) is listed on NASDAQ. Its market capitalization is about $4B. On trailing-twelve-month earnings the P/E ratio is -13.61, and the P/B ratio is 4.88. Return on equity is -35.9%. These figures are computed in-house from official filings and are reference information only.

Relay Therapeutics — frequently asked questions

What is the P/E ratio of Relay Therapeutics (RLAY)?
On a trailing-twelve-month basis, RLAY trades at a P/E ratio of -13.61. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Relay Therapeutics?
RLAY has a market capitalization of about $4B. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.